Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Horwitz

Showing results (651-660 of 717) with videos related to

Pageof 72
Sort By:
JAMA Psychiatry|November 29, 2013
Parsing dimensional vs diagnostic category-related patterns of reward circuitry function in behaviorally and emotionally dysregulated youth in the Longitudinal Assessment of Manic Symptoms studyGenna Bebko, Michele A Bertocci, Jay C Fournier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 VaccineRebecca M Shulman, David S Weinberg, Eric A Ross, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.
Blood Advances|July 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell LymphomaSean E Healton, Manik Uppal, Pallavi K Galera, et al.
Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.
Pageof 72

Showing results (651-660 of 717) with videos related to

Sort By:
Pageof 72
JAMA Psychiatry|November 29, 2013
Parsing dimensional vs diagnostic category-related patterns of reward circuitry function in behaviorally and emotionally dysregulated youth in the Longitudinal Assessment of Manic Symptoms studyGenna Bebko, Michele A Bertocci, Jay C Fournier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 VaccineRebecca M Shulman, David S Weinberg, Eric A Ross, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.
Blood Advances|July 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell LymphomaSean E Healton, Manik Uppal, Pallavi K Galera, et al.
Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.
Pageof 72